The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 million in its initial public offering, Exscientia (EXAI -4.17%) has thrown in the towel and agreed to merge with Recursion Pharmaceuticals (RXRX -5.27%), another AI-driven drug developer. In a nutshell, these ...